Kexing Biopharm Co., Ltd.SSE: 688136

SHAN DONG KEXING BIOPRODUCTS CO., LTD.: Announcement on Change of Sponsor Representative for Continuous Supervision

Aug 8, 2026 · Issued by Kexing Biopharm Co., Ltd. via Shanghai Stock Exchange

Filed with SSE · Aug 8, 2026

On 6ix: 6ix.com/news/shan-dong-kexing-bioproducts-co-ltdannouncement-on-change-of-sponsor-representative-for-continuous-supervision

Announcement on Change of Sponsor Representative for Continuous Supervision

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference:
View Attachment

6ix hasn’t read this filing yet.

Kexing Biopharm Co., Ltd. on 6ix

Story so far

SHAN DONG KEXING BIOPRODUCTS CO., LTD.: Announcement on Vesting Results for the 2nd Vesting Period under the 2024 Restricted Stock Incentive Plan and the Listing of SharesJul 8, 2026
SHAN DONG KEXING BIOPRODUCTS CO., LTD.: Announcement on Granting of Restricted Stocks to Incentive ObjectsJul 3, 2026
Indicative Announcement on Report on Results of Shareholders' Inquiry Transfer and Equity Change of Shareholders with Over 5% Shares Reaching 5% Integer MultipleNov 21, 2025

Earlier from Kexing Biopharm

SHAN DONG KEXING BIOPRODUCTS CO., LTD.: Announcement on Vesting Results for the 2nd Vesting Period under the 2024 Restricted Stock Incentive Plan and the Listing of SharesJul 8
SHAN DONG KEXING BIOPRODUCTS CO., LTD.: Announcement on Granting of Restricted Stocks to Incentive ObjectsJul 3
Announcement on the Resignation of Core Technical PersonnelJun 27
Beyond Horizons, Forward Together | Kexing Biopharm Concludes Participation in CPHI & PMEC China 2026Jun 23
Announcement on the Achievements of Vesting Conditions in the 2nd Vesting Period of the 2024 Restricted Stock Incentive PlanJun 16

Later from Kexing Biopharm

SHAN DONG KEXING BIOPRODUCTS CO., LTD.: Special Report on the Deposit, Management and Actual Use of Raised Funds for the First Half of 2026Aug 22
SHAN DONG KEXING BIOPRODUCTS CO., LTD.: Announcement on Participating in the 2026 Semi-annual Collective Performance Briefing for the STAR Market Innovative Drug IndustrySep 8
SHAN DONG KEXING BIOPRODUCTS CO., LTD.: Announcement on Voluntary Disclosure of Receipt of the Clinical Trial Approval Notice for GB20 InjectionSep 22
Kexing Biopharm's Investigational Anti-TL1A Monoclonal Antibody GB20 Cleared for Clinical Trials in ChinaOct 4
(688136)"SHAN DONG KEXING BIOPRODUCTS CO., LTD."Announcement on Voluntary Disclosure of Acceptance of Marketing Authorization Application for Pegylated Human Granulocyte Colony-Stimulating Factor InjectionOct 10

All Kexing Biopharm news releases

Follow Kexing Biopharm into a list and get an email when it puts out news.

Follow Kexing Biopharm